Last updated: August 1, 2026
Executive summary
DOW PHARMACEUTICAL SCIENCES, INC. v. TOLMAR, INC. (2:15-cv-07971) is a federal patent litigation in the US District Court for the District of New Jersey between Dow and Tolmar. The matter concerns Dow’s patent rights tied to an FDA-regulated pharmaceutical product and Tolmar’s parallel commercial and/or abbreviated regulatory activity. The case number indicates a Hatch-Waxman style posture is likely, but the specific patents-in-suit, asserted claims, and the dispositive outcomes (dismissal, summary judgment, settlement, consent judgment, or trial judgment) are not present in the information provided here, so a complete litigation summary cannot be produced to a litigation-grade standard.
What is DOW PHARMACEUTICAL SCIENCES v. TOLMAR, INC. 2:15-cv-07971 about?
A complete case summary requires the docket’s substantive entries: the patents-in-suit (numbers), the asserted claims, the filing of an ANDA (or 505(b)(2)) and the associated Orange Book listing, and the relief sought in the complaint. Those elements are not included in the supplied case identifier alone.
Which patents were asserted in the case?
The litigation-grade answer depends on the complaint’s “List of Patent(s) Asserted” section and any amended schedules. The patent numbers, assignees, and expiration dates cannot be stated from the case caption and docket number alone.
What product and regulatory posture drove the dispute?
Case identifiers of this form often track Hatch-Waxman timing between an innovator’s listed patents and a generic filer’s Paragraph IV certification or other FDA pathway. The specific drug, NDA/ANDA number, and certification type are not provided here.
What was Tolmar’s alleged infringement theory?
A precise infringement analysis requires claim charts or at least the complaint’s theory: direct infringement, induced infringement, or infringement of methods of use, along with each accused formulation or manufacturing step. None of that is included in the provided data.
What happened procedurally in the litigation?
A procedural timeline must be built from docket events (complaint filing, answer, Rule 12 motions, claim construction schedule, discovery rulings, summary judgment motions, trial dates, and orders). Without the docket event data, the procedural history cannot be reconstructed accurately.
Key procedural milestones usually tracked
- Complaint and service timeline
- Responsive pleading and Rule 12/pleading amendments
- Claim construction (Markman) schedule and rulings
- Discovery scope and scheduling orders
- Dispositive motions (summary judgment, JMOL, or consent judgment)
- Status conference outcomes
- Settlement or final judgment entry
No such milestones are included in the supplied information.
What does the case say about patent validity and enforceability?
A validity and enforceability analysis must identify:
- the invalidity grounds (anticipation, obviousness, indefiniteness, enablement, written description, etc.)
- the prior art asserted
- any inequitable conduct allegations
- whether the court issued findings on §102/§103/§112 and on enforceability
None of those specifics are available from the case caption and number alone.
What is the Orange Book status tied to this litigation?
Orange Book status requires the drug’s NDA number and the listed patents that correspond to the asserted patents-in-suit. The provided information does not include:
- NDA/ANDA identifiers
- listed patent numbers
- expiration dates or pediatric exclusivity or patent term adjustment data
- any “delistings” or re-listings
So the Orange Book mapping cannot be completed.
When did exclusivity or patent expiration intersect with Tolmar’s FDA filing?
A Hatch-Waxman overlap analysis is driven by:
- innovator patent expiration and any PTA/PTE adjustments
- 30-month stay trigger dates from a Paragraph IV notice
- market exclusivity end dates (NCE, 7.5/5/3-year exclusivity)
- final court decision timing and any settlement-based “carve-out” or launch date
Those dates are not present in the provided input.
What is the settlement or injunction posture for this case?
A settlement analysis needs evidence of a settlement agreement or court-ordered consent judgment:
- whether a “30-month stay” was lifted by entry of an injunction
- whether Tolmar received a launch date in exchange for noninfringement/non-assert terms
- whether the case ended with dismissal, consent judgment, or final merits judgment
No such termination outcome data is provided.
How strong was the asserted patent estate for Dow vs Tolmar’s generic risk?
Assessing “patent estate strength” requires:
- the number of unexpired patents at filing and at any notice date
- independent vs dependent claim coverage (scope)
- likelihood of design-around paths
- whether any patents were invalidated or narrowed during litigation
None of those data points are supplied.
Formulation and method-of-use coverage
If the asserted patents cover formulation, composition-of-matter, polymorphs, release profiles, or methods of use, that must be mapped to claim language and manufacturing parameters. No formulation/method details are available.
Which court rulings drove the outcome (motions, claim construction, summary judgment)?
A definitive answer needs citations to the court’s orders:
- denial/grant of motions to dismiss
- claim construction outcomes impacting infringement/validity
- summary judgment results
- evidentiary rulings affecting trial posture
No orders are provided.
Geographic scope: was this US-only or tied to broader enforcement?
The case is US federal litigation. A broader enforcement picture requires additional litigation in other districts or countries and any parallel proceedings. Only the US case number is given, so the geographic scope cannot be confirmed beyond the forum.
Key takeaways
- The case identifier “DOW PHARMACEUTICAL SCIENCES, INC. v. TOLMAR, INC. | 2:15-cv-07971” indicates a US patent dispute, but the record needed for a litigation summary is not included.
- Without patents-in-suit, product identity, docket events, and final disposition details, no accurate infringement/validity narrative or outcome analysis can be produced.
FAQs
- What patents were asserted in DOW PHARMACEUTICAL SCIENCES, INC. v. TOLMAR, INC. (2:15-cv-07971)?
- What FDA application (ANDA/NDA) and Orange Book listed patents were linked to 2:15-cv-07971?
- Did Tolmar file a Paragraph IV certification that triggered the 30-month stay in 2:15-cv-07971?
- What was the final disposition of the case, and did the court issue an injunction or consent judgment?
- Were any patents held invalid, narrowed, or enforced in DOW v. TOLMAR 2:15-cv-07971?
References
No sources were provided in the prompt to cite.
